Cytokinetics price target raised to $13 from $12 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Cytokinetics and raised his price target on shares to $13 from $12 after Cytokinetics and its partners announced that omecamtiv mecarbil has passed a futility analysis in the Phase III GALACTIC-HF trial, which will continue enrolling ~8,000 HFrEF patients. The analyst anticipates an interim efficacy analysis in 2020, prior to final data likely in 2021.